These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31925644)

  • 1. NLRC5: new cancer buster?
    Tang F; Xu Y; Zhao B
    Mol Biol Rep; 2020 Mar; 47(3):2265-2277. PubMed ID: 31925644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NLRC5/CITA: A Key Player in Cancer Immune Surveillance.
    Yoshihama S; Vijayan S; Sidiq T; Kobayashi KS
    Trends Cancer; 2017 Jan; 3(1):28-38. PubMed ID: 28718425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
    Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
    Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.
    Ong CEB; Patchett AL; Darby JM; Chen J; Liu GS; Lyons AB; Woods GM; Flies AS
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1973-1991. PubMed ID: 33797607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
    Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
    Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.
    Shukla A; Cloutier M; Appiya Santharam M; Ramanathan S; Ilangumaran S
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC class I transactivator NLRC5 in host immunity, cancer and beyond.
    Cho SX; Vijayan S; Yoo JS; Watanabe T; Ouda R; An N; Kobayashi KS
    Immunology; 2021 Mar; 162(3):252-261. PubMed ID: 32633419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5.
    Chelbi ST; Dang AT; Guarda G
    Adv Immunol; 2017; 133():89-119. PubMed ID: 28215281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
    Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
    Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I-deficient breast cancer cells.
    Zhao MZ; Sun Y; Jiang XF; Liu L; Liu L; Sun LX
    Immunol Res; 2019 Dec; 67(6):497-504. PubMed ID: 31900803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.
    Meissner TB; Li A; Biswas A; Lee KH; Liu YJ; Bayir E; Iliopoulos D; van den Elsen PJ; Kobayashi KS
    Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13794-9. PubMed ID: 20639463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression regulation and function of NLRC5.
    Yao Y; Qian Y
    Protein Cell; 2013 Mar; 4(3):168-75. PubMed ID: 23483478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.
    Ludigs K; Seguín-Estévez Q; Lemeille S; Ferrero I; Rota G; Chelbi S; Mattmann C; MacDonald HR; Reith W; Guarda G
    PLoS Genet; 2015 Mar; 11(3):e1005088. PubMed ID: 25811463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma.
    Wang Q; Ding H; He Y; Li X; Cheng Y; Xu Q; Yang Y; Liao G; Meng X; Huang C; Li J
    Cancer Lett; 2019 Mar; 444():9-19. PubMed ID: 30543814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.
    Meissner TB; Li A; Liu YJ; Gagnon E; Kobayashi KS
    Biochem Biophys Res Commun; 2012 Feb; 418(4):786-91. PubMed ID: 22310711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity.
    Santharam MA; Shukla A; Levesque D; Kufer TA; Boisvert FM; Ramanathan S; Ilangumaran S
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRC5/MHC class I transactivator: A key target for immune escape by SARS-CoV-2.
    Zhu B; Ouda R; Kasuga Y; de Figueiredo P; Kobayashi KS
    Bioessays; 2024 Apr; 46(4):e2300109. PubMed ID: 38461519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer.
    Zhan L; Zhang J; Wei B; Cao Y
    Autophagy; 2022 Apr; 18(4):942-943. PubMed ID: 35174769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of immune pathways by the NOD-like receptor NLRC5.
    Lamkanfi M; Kanneganti TD
    Immunobiology; 2012 Jan; 217(1):13-6. PubMed ID: 22024701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NLRC5 deficiency protects against acute kidney injury in mice by mediating carcinoembryonic antigen-related cell adhesion molecule 1 signaling.
    Li Q; Wang Z; Zhang Y; Zhu J; Li L; Wang X; Cui X; Sun Y; Tang W; Gao C; Ma C; Yi F
    Kidney Int; 2018 Sep; 94(3):551-566. PubMed ID: 29907459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.